文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

以呼吸频率与膈肌增厚分数比值(RR/DTF)为导向的风险预测模型对慢性阻塞性肺疾病急性加重患者无创-有创机械通气转换时机的预测价值

[Predictive value of a risk prediction model guided by the ratio of respiratory rate to diaphragmatic thickening fraction for the timing of noninvasive-invasive mechanical ventilation transition in patients with acute exacerbation of chronic obstructive pulmonary disease].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论在AECOPD接受NIV的患者中,NIV后2小时RR/DTF、RR、PaCO2、VT、排痰障碍是无创通气失败的独立危险因素,RR/DTF导向模型的AUC为0.713,最佳cut-off为0.87。

该研究纳入2022年1月至2023年7月锦州医科大学附属第一医院重症医学科收治的64例确诊AECOPD并接受无创通气的患者,按24小时内NIV结局分为成功组43例与失败组21例,比较NIV 2小时后的RR/DTF、膈肌移动度、潮气量、呼吸频率、pH、PaCO2及排痰障碍。失败组RR/DTF、RR、PaCO2及排痰障碍均显著高于成功组,VT与DE显著降低(均P<0.05)。二元Logistic回归显示RR/DTF(OR=147.989,95%CI 3.321-595.412,P=0.010)、RR(OR=1.296,95%CI 1.006-1.670,P=0.045)、VT(OR=0.966,95%CI 0.935-0.999,P=0.044)、PaCO2(OR=1.086,95%CI 1.006-1.173,P=0.035)、排痰障碍(OR=4.533,95%CI 1.025-20.049,P=0.046)为NIV失败的独立危险因素。ROC曲线AUC为0.713(95%CI 0.587-0.839,P=0.005),敏感度72.73%、特异度88.10%、约登指数0.394、最佳cut-off 0.87。作者认为该模型对AECOPD无创-有创机械通气转换时机有较好的预测价值。

要点

  • AECOPD患者NIV 2小时后RR/DTF在失败组为1.00±0.18、成功组为0.89±0.22,失败组显著升高(P<0.05)。
  • 二元Logistic回归中RR/DTF为NIV失败的独立危险因素(OR=147.989,95%CI 3.321-595.412,P=0.010)。
  • RR/DTF导向风险预测模型预测NIV失败的AUC为0.713(95%CI 0.587-0.839,P=0.005),最佳cut-off为0.87,敏感度72.73%、特异度88.10%、约登指数0.394。
  • NIV失败组排痰障碍占57.1%,成功组占30.2%(P<0.05);排痰障碍OR=4.533(95%CI 1.025-20.049,P=0.046)。
  • NIV失败组VT为308.09±14.89 mL、成功组为324.48±23.82 mL,失败组显著降低(P<0.05),VT的OR=0.966(95%CI 0.935-0.999,P=0.044)。

适用人群与场景

  • 2022年1月至2023年7月锦州医科大学附属第一医院重症医学科收治、确诊AECOPD并接受无创通气的患者64例。
  • 按24小时内NIV结局分为NIV成功组43例与NIV失败组21例。

诊断标准与关键阈值

  • NIV结局分组依据为24小时内无创通气结局。
  • RR/DTF导向风险预测模型预测NIV失败的最佳cut-off值为0.87。

研究设计与关键结果

  • 单中心研究,纳入64例AECOPD接受NIV患者,NIV成功组43例、NIV失败组21例;两组年龄、性别、BMI、氧合指数(P/F)、吸烟史、APACHEⅡ等基线资料差异无统计学意义,具有可比性。
  • NIV 2小时后,失败组较成功组:RR/DTF(%)1.00±0.18 vs. 0.89±0.22、RR(bpm)21.64±3.13 vs. 19.62±2.98、PaCO2(mmHg,1 mmHg≈0.133 kPa)70.82±8.82 vs. 65.29±9.47、排痰障碍57.1% vs. 30.2%均显著升高(均P<0.05);VT(mL)308.09±14.89 vs. 324.48±23.82、DE(mm)19.91±2.94 vs. 22.05±3.30显著降低(均P<0.05)。
  • 二元Logistic回归显示预测AECOPD患者NIV失败的独立危险因素:RR/DTF(OR=147.989,95%CI 3.321-595.412,P=0.010)、RR(OR=1.296,95%CI 1.006-1.670,P=0.045)、VT(OR=0.966,95%CI 0.935-0.999,P=0.044)、PaCO2(OR=1.086,95%CI 1.006-1.173,P=0.035)、排痰障碍(OR=4.533,95%CI 1.025-20.049,P=0.046)。
  • ROC曲线分析:AUC为0.713(95%CI 0.587-0.839,P=0.005),敏感度72.73%,特异度88.10%,约登指数0.394,最佳cut-off值0.87。

证据类型、等级与局限

  • 证据类型:单中心临床研究(摘要未标注具体研究设计类型);证据等级:原文未给出。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,RR/DTF风险预测模型对AECOPD患者无创-有创机械通气转换时机具有较好的预测价值,可用于NIV 2小时后评估失败风险并辅助转换时机判断。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the predictive value of a risk prediction model guided by the ratio of respiratory rate to diaphragm thickening fraction (RR/DTF) for noninvasive-invasive mechanical ventilation transition timing in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), through ultrasound evaluation of diaphragm movement indicators.

METHODS: Sixty-four patients diagnosed with AECOPD and undergoing non-invasive ventilation (NIV), who were admitted to the department of critical care medicine of the First Affiliated Hospital of Jinzhou Medical University from January 2022 to July 2023 were enrolled. They were divided into NIV successful group and NIV failure group based on the outcome of NIV within 24 hours. Clinical indicators such as RR/DTF, diaphragmatic excursion (DE), tidal volume (VT), respiratory rate (RR), pH value, partial pressure of carbon dioxide (PaCO2), and sputum excretion disorder were compared between the two groups after 2 hours of NIV. The factors influencing NIV failure were included in binary Logistic regression analysis, and an RR/DTF oriented risk prediction model was established. Receiver operator characteristic curve (ROC curve) analysis was used to assess the predictive value of this model for the timing of noninvasive-invasive mechanical ventilation transition in AECOPD patients.

RESULTS: Among 64 patients with AECOPD, with 43 in the NIV successful group and 21 in the NIV failure group. There were no statistically significant differences in baseline data such as age, gender, body mass index (BMI), oxygenation index (P/F), smoking history, and acute physiological and chronic health evaluation II (APACHE II) between the two groups of patients, indicating comparability. Compared to the NIV successful group, the NIV failure group showed a significantly increase in RR/DTF, RR, PaCO2, and sputum retention, while VT and DE were significantly decreased [RR/DTF (%): 1.00±0.18 vs. 0.89±0.22, RR (bpm): 21.64±3.13 vs. 19.62±2.98, PaCO2 (mmHg, 1 mmHg ≈ 0.133 kPa): 70.82±8.82 vs. 65.29±9.47, sputum retention: 57.1% vs. 30.2%, VT (mL): 308.09±14.89 vs. 324.48±23.82, DE (mm): 19.91±2.94 vs. 22.05±3.30, all P < 0.05]. Binary Logistic regression analysis showed that RR/DTF [odds ratio (OR) = 147.989, 95% confidence interval (95%CI) was 3.321-595.412, P = 0.010], RR (OR = 1.296, 95%CI was 1.006-1.670, P = 0.045), VT (OR = 0.966, 95%CI was 0.935-0.999, P = 0.044), PaCO2 (OR = 1.086, 95%CI was 1.006~1.173, P = 0.035), and sputum retention (OR = 4.533, 95%CI was 1.025-20.049, P = 0.046) were independent risk factors for predicting NIV failure in AECOPD patients. ROC curve analysis showed that the area under the curve (AUC) of 0.713 with a 95%CI of 0.587-0.839 (P = 0.005). The sensitivity was 72.73%, the specificity was 88.10%, the Youden index was 0.394, and the optimal cut-off value was 0.87.

CONCLUSIONS: The RR/DTF risk prediction model has good predictive value for the timing of noninvasive-invasive mechanical ventilation transition in AECOPD patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li X, Li T, Di X, et al. [Predictive value of a risk prediction model guided by the ratio of respiratory rate to diaphragmatic thickening fraction for the timing of noninvasive-invasive mechanical ventilation transition in patients with acute exacerbation of chronic obstructive pulmonary disease]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38845497. doi:10.3760/cma.j.cn121430-20231205-01051

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。